Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes. For patients with a diagnosis of cancer in the setting of a known inherited syndrome, the management of that cancer often involves different systemic therapy options, surgical decisions, and posttreatment surveillance and survivorship considerations.
Advances in next-generation sequencing (NGS) technologies have drastically improved both the cost and efficiency of germline genetic testing, and a wide array of multigene panels have become commercially available to clinically assess patients for a broad spectrum of inherited cancer risks. Read more . . .